Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 4/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586773 | 0.81 | IDO1 (0.48) | GLO1KDM4E | |
| SCHEMBL8536250 | 0.75 | PTGES2 (0.46) | GLO1DRD2DRD4DRD3RIPK1 | |
| SCHEMBL10325404 | 0.72 | IDO1 (0.53) | GLO1KDM4E | |
| SCHEMBL14292147 | 0.72 | CDC25B (0.57) | DRD2DRD4DRD3RIPK1KDM4E | |
| SCHEMBL3492565 | 0.72 | DRD2 (0.58) | GLO1DRD2DRD4DRD3RIPK1 | |
| SCHEMBL5397113 | 0.71 | GLO1 (0.48) | GLO1TSHRKDM4EBRD4MEN1 | |
| SCHEMBL6491355 | 0.69 | CA2 (0.55) | GLO1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL6988614 | 0.68 | MET (0.49) | GLO1RIPK1DAOMEN1KMT2A | |
| SCHEMBL2113619 | 0.67 | DRD2 (0.53) | DRD2DRD4DRD3RIPK1DAO | |
| SCHEMBL9597342 | 0.67 | GLO1 (0.49) | GLO1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | EIF2AK2, MAVS, ZC3HAV1 | GLO1 2881/4885DRD2 4310/4885DRD4 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.